No Data
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Piper Sandler Reiterates Overweight on Skye Bioscience, Maintains $20 Price Target
Skye Bioscience Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity.
JMP Securities Maintains SKYE BIOSCIENCE INC(SKYE.US) With Buy Rating, Maintains Target Price $15
JMP Securities analyst Jonathan Wolleben maintains $SKYE BIOSCIENCE INC(SKYE.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate
US Stocks Edge Lower; FedEx Earnings Miss Views
Skye Bioscience Initiated at Market Outperform by JMP Securities